Compare · EKSO vs TMO
EKSO vs TMO
Side-by-side comparison of Ekso Bionics Holdings Inc. (EKSO) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EKSO and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $257.53B, about 6124.6x EKSO ($42.0M).
- Over the past year, EKSO is up 144.0% and TMO is up 28.0% - EKSO leads by 116.0 points.
- EKSO has been more active in the news (24 items in the past 4 weeks vs 7 for TMO).
- TMO has more recent analyst coverage (25 ratings vs 0 for EKSO).
- Company
- Ekso Bionics Holdings Inc.
- Thermo Fisher Scientific Inc
- Price
- $11.37-1.52%
- $690.13-0.92%
- Market cap
- $42.0M
- $257.53B
- 1M return
- +22.26%
- +4.77%
- 1Y return
- +143.99%
- +28.01%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 24
- 7
- Recent ratings
- 0
- 25
Ekso Bionics Holdings Inc.
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the United States and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, sells, and rents exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, sells, and rents exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation and OttoBock Healthcare Product GmbH. The company was founded in 2005 and is headquartered in Richmond, California.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest EKSO
- SEC Form DEFA14A filed by Ekso Bionics Holdings Inc.
- SEC Form 8-K filed by Ekso Bionics Holdings Inc.
- ChronoScale Reports Fiscal First Quarter 2027 Results
- SEC Form 10-Q filed by Ekso Bionics Holdings Inc.
- SEC Form EFFECT filed by Ekso Bionics Holdings Inc.
- SEC Form 4 filed by Ekso Bionics Holdings Inc.
- SEC Form S-8 POS filed by Ekso Bionics Holdings Inc.
- SEC Form S-8 POS filed by Ekso Bionics Holdings Inc.
- SEC Form S-8 POS filed by Ekso Bionics Holdings Inc.
- SEC Form 8-K filed by Ekso Bionics Holdings Inc.
Latest TMO
- SEC Form 4 filed by Director Weisler Dion J
- SEC Form 4 filed by Director Sperling Scott M
- SEC Form 4 filed by Director Lynch Karen S
- SEC Form 4 filed by Director Johnson Jennifer M
- SEC Form 4 filed by Director Keith R. Alexandra
- Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
- Thermo Fisher Scientific Launches Gibco™ CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development
- Thermo Fisher upgraded by UBS with a new price target
- CLSA initiated coverage on Thermo Fisher with a new price target
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)